SCARA5 and hepatocellular carcinoma: Studies have shown that SCARA5 deficiency suppresses ferroptosis in tumour cells, thereby impairing immune activation within the TME and increasing the resistance of hepatocellular carcinoma (HCC) cells to sorafenib [25].